Methadone-maintained patients in primary care have higher rates of chronic disease and multimorbidity, and use health services more intensively than matched controls

European Journal of General Practice

Volumn 20, Issue 4, 2014, Pages 275-280

  O'Toole, John ^a   Hambly, Róisín ^a   Cox, Anne Marie ^a   O'Shea, Brendan ^a   Darker, Catherine ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Chronic disease; Health care costs; Health policy; Methadone; Primary health care

Indexed keywords

METHADONE; NARCOTIC ANALGESIC AGENT;

ADDICTION; ADULT; AGED; ALCOHOL ABUSE; AMBULATORY CARE; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; COMORBIDITY; CONTROLLED STUDY; EMERGENCY WARD; ENDOCRINE DISEASE; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HUMAN; INFECTION; IRELAND; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MENTAL DISEASE; METHADONE TREATMENT; NURSING ASSESSMENT; OBESITY; OUTPATIENT CARE; PATIENT ASSESSMENT; PRIMARY HEALTH CARE; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SECONDARY HEALTH CARE; SMOKING; SUBSTANCE USE; TELECONSULTATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; FOLLOW UP; HEALTH SERVICE; HOSPITALIZATION; MULTICENTER STUDY; OPIATE SUBSTITUTION TREATMENT; PROCEDURES; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADULT; ANALGESICS, OPIOID; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH SERVICES; HOSPITALIZATION; HUMANS; IRELAND; MALE; METHADONE; OPIATE SUBSTITUTION TREATMENT; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 84910644354     PISSN: 13814788     EISSN: 17511402     Source Type: Journal    
DOI: 10.3109/13814788.2014.905912     Document Type: Article

References (30)

1. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2013: Trends and developments. Lisbon: EMCDDA, Publications office of the European Union; 2013. pp. 38-42.
2. European Monitoring Centre for Drugs and Drug Addiction. The state of the drugs problem in Europe. Annual Report 2012. Luxembourg: EMCDDA, Publications Office of the European Union; 2012. pp. 72-6.
3. Farrell M, Barry J. The introduction of the opioid treatment protocol. Dublin: Department of Health, Health Service Executive; 2010. pp. 33-6.
4. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization, Department of Mental Health and Substance Abuse; 2009. pp. 31.
5. World Health Organization. Proposal for the inclusion of metha-done in the WHO model list of essential medicines. Geneva: World Health Organization, Department of Mental Health and Substance Use; 2004. pp. 22.
6. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technol Assess. 2007;11:1-171.
7. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011:CD004145.
8. Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, et al. Survival and cessation in injecting drug users: Prospective observational study of outcomes and Effect of opiate substitution treatment. Br Med J. 2010; 341: c3172.
9. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009:CD002209.
10. National Treatment Agency for Substance Misuse. Why invest? How drug treatment and recovery services work for individuals, communities and society. London: NHS, National Treatment Agency for Substance Misuse; 2011. pp. 7.
11. Salamina G, Diecidue R, Vigna-Taglianti F, Jarre P, Schifano P, Bargagli AM, et al. Effectiveness of therapies for heroin addiction in retaining patients in treatment: Results from the VEdeTTE study. Subst Use Misuse 2010; 45: 2076-92.
12. Martin E, Canavan A, Butler R. A decade of caring for drug users entirely within general practice. Br J Gen Pract. 1998; 48: 1679-82.
13. Keen J, Rowse G, Mathers N, Campbell M, Seivewright N. Can methadone maintenance for heroin-dependent patients retained in general practice reduce criminal conviction rates and time spent in prison? Br J Gen Pract. 2000;50:48-9.
14. Keen J, Oliver P, Mathers N. Methadone maintenance treatment can be provided in a primary care setting without increasing methadone-related mortality: The Sheffield experience 1997-2000. Br J Gen Pract. 2002;52:387-9.
15. Keenan E, Barry J. Managing drug misuse in general practice. Republic of Ireland has set up scheme to regulate methadone prescribing by GPs. Br Med J. 1999; 319: 1497.
16. Gossop M, Marsden J, Stewart D, Lehmann P, Strang J. Methadone treatment practices and outcome for opiate addicts treated in drug clinics and in general practice: Results from the national treatment outcome research study. Br J Gen Pract. 1999; 49:31-4.
17. Gossop M, Marsden J, Stewart D, Lehmann P, Edwards C, Wilson A, et al. Substance use, health and social problems of service users at 54 drug treatment agencies. Intake data from the national treatment outcome research study. Br J Psychiatry 1998; 173:166-71.
18. Rosen D, Smith ML, Reynolds CF 3rd. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry 2008;16:488-97.
19. Ryan CF, White JM. Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction 1996;91:39-45.
20. Maruyama A, Macdonald S, Borycki E, Zhao J. Hypertension, chronic obstructive pulmonary disease, diabetes and depression among older methadone maintenance patients in British Columbia. Drug Alcohol Rev. 2013;32:412-8.
21. Savant JD, Barry DT, Cutter CJ, Joy MT, Dinh A, Schottenfeld RS, et al. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment. Drug Alcohol Depend. 2013;127:243-7.
22. Cullen W, O'Brien S, O'Carroll A, O'Kelly FD, Bury G. Chronic illness and multimorbidity among problem drug users: A comparative cross sectional pilot study in primary care. BMC Fam Pract. 2009; 10: 25.
23. Primary Care Reimbursement Service. Statistical analysis of claims and payments 2010. Dublin: Department of Health, Health Service Executive; 2011. pp. 42.
24. van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. Multimorbidity in general practice: Prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol. 1998; 51: 367-75.
25. Tabachnick BG, Fidell LS. Logistic regression. In: Using multivariate statistics. 5th ed. Boston: Allyn & Bacon; 2007. pp. 437-504.
26. Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med. 2005;3:223-8.
27. Fortin M, Hudon C, Haggerty J, Akker M, Almirall J. Prevalence estimates of multimorbidity: A comparative study of two sources. BMC Health Serv Res. 2010;10:111.
28. Darker CD, Sweeney BP, El Hassan HO, Smyth BP, Ivers JH, Barry JM. Brief interventions are Effective in reducing alcohol consumption in opiate-dependent methadone-maintained patients: Results from an implementation study. Drug Alcohol Rev. 2012; 31: 348-56.
29. Nahvi S, Richter K, Li X, Modali L, Arnsten J. Cigarette smoking and interest in quitting in methadone maintenance patients. Addict Behav. 2006;31:2127-34.
30. Palmer F, Jaffray M, Moffat MA, Matheson C, McLernon DJ, Coutts A, et al. Prevalence of common chronic respiratory diseases in drug misusers: A cohort study. Prim Care Respir J. 2012;21:377-83.